18f-fmau
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 22, 2013 (NCT01712815)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-fmau
- fluorine f 18-clevudine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04752267 | Early Phase 1 (Phase 1) | Feb 15, 2021 | National Cancer Institute (NCI), University of Southern California |
| NCT01712815 | N/A | Nov 22, 2013 | National Cancer Institute (NCI), University of Southern California |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2013 |
| University of Southern California | Academic/Hospital | 2 | 2 | 2 | 2013 |
2 organizations
Page 1 / 1